AU2008259618A1 - Transgenic animals for assessing drug metabolism and toxicity - Google Patents
Transgenic animals for assessing drug metabolism and toxicity Download PDFInfo
- Publication number
- AU2008259618A1 AU2008259618A1 AU2008259618A AU2008259618A AU2008259618A1 AU 2008259618 A1 AU2008259618 A1 AU 2008259618A1 AU 2008259618 A AU2008259618 A AU 2008259618A AU 2008259618 A AU2008259618 A AU 2008259618A AU 2008259618 A1 AU2008259618 A1 AU 2008259618A1
- Authority
- AU
- Australia
- Prior art keywords
- human
- tissue
- mouse
- dna sequence
- hupxr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims description 193
- 230000009261 transgenic effect Effects 0.000 title claims description 108
- 230000036267 drug metabolism Effects 0.000 title claims description 70
- 230000001988 toxicity Effects 0.000 title claims description 37
- 231100000419 toxicity Toxicity 0.000 title claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 765
- 108090000623 proteins and genes Proteins 0.000 claims description 340
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 313
- 230000014509 gene expression Effects 0.000 claims description 270
- 239000003814 drug Substances 0.000 claims description 226
- 229940079593 drug Drugs 0.000 claims description 226
- 108010001511 Pregnane X Receptor Proteins 0.000 claims description 206
- 230000000694 effects Effects 0.000 claims description 157
- 108090000790 Enzymes Proteins 0.000 claims description 137
- 102000004190 Enzymes Human genes 0.000 claims description 132
- 108091023040 Transcription factor Proteins 0.000 claims description 120
- 102000040945 Transcription factor Human genes 0.000 claims description 116
- 230000008685 targeting Effects 0.000 claims description 109
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 230000006698 induction Effects 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 89
- 101100187477 Homo sapiens NR1I2 gene Proteins 0.000 claims description 86
- 108010078791 Carrier Proteins Proteins 0.000 claims description 83
- 230000001105 regulatory effect Effects 0.000 claims description 75
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 75
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 72
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 72
- 229960001225 rifampicin Drugs 0.000 claims description 71
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 64
- 229960003957 dexamethasone Drugs 0.000 claims description 64
- 230000001404 mediated effect Effects 0.000 claims description 62
- 239000013598 vector Substances 0.000 claims description 60
- 230000004060 metabolic process Effects 0.000 claims description 54
- 108700008625 Reporter Genes Proteins 0.000 claims description 52
- 238000003556 assay Methods 0.000 claims description 50
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 47
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 47
- BAFKRPOFIYPKBQ-UHFFFAOYSA-N 3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine Chemical compound ClC1=CC(Cl)=CN=C1OC(C=C1)=CC=C1OC1=NC=C(Cl)C=C1Cl BAFKRPOFIYPKBQ-UHFFFAOYSA-N 0.000 claims description 42
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 claims description 38
- 239000002299 complementary DNA Substances 0.000 claims description 38
- 108700024394 Exon Proteins 0.000 claims description 36
- 238000012217 deletion Methods 0.000 claims description 33
- 230000037430 deletion Effects 0.000 claims description 33
- ZQWBOKJVVYNKTL-AUEPDCJTSA-N (e)-1-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]-n-[(3,4-dichlorophenyl)methoxy]methanimine Chemical compound C1=CC(Cl)=CC=C1C1=C(\C=N\OCC=2C=C(Cl)C(Cl)=CC=2)N2C=CSC2=N1 ZQWBOKJVVYNKTL-AUEPDCJTSA-N 0.000 claims description 30
- 241001529936 Murinae Species 0.000 claims description 29
- 108091008053 gene clusters Proteins 0.000 claims description 28
- 108020004414 DNA Proteins 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 238000011830 transgenic mouse model Methods 0.000 claims description 27
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 claims description 25
- 101150014691 PPARA gene Proteins 0.000 claims description 23
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 22
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 22
- 102000044284 human CYP3A4 Human genes 0.000 claims description 22
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims description 21
- 102000053576 human ABCB1 Human genes 0.000 claims description 21
- 238000013518 transcription Methods 0.000 claims description 21
- 230000035897 transcription Effects 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 20
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 18
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 claims description 18
- 108010029485 Protein Isoforms Proteins 0.000 claims description 18
- 102000001708 Protein Isoforms Human genes 0.000 claims description 18
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 17
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 230000022814 xenobiotic metabolic process Effects 0.000 claims description 17
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims description 16
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 claims description 16
- 101100187479 Mus musculus Nr1i2 gene Proteins 0.000 claims description 15
- 101100168383 Rattus norvegicus Cyp2c11 gene Proteins 0.000 claims description 15
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 claims description 13
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 claims description 13
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 claims description 13
- 241000283984 Rodentia Species 0.000 claims description 13
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 12
- 108091092195 Intron Proteins 0.000 claims description 12
- 101000858032 Mus musculus Coxsackievirus and adenovirus receptor homolog Proteins 0.000 claims description 12
- 101001124276 Mus musculus Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 claims description 12
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 claims description 12
- 101100329196 Homo sapiens CYP2D6 gene Proteins 0.000 claims description 11
- 102000048369 human CYP2C9 Human genes 0.000 claims description 11
- 238000013519 translation Methods 0.000 claims description 11
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 10
- 230000007686 hepatotoxicity Effects 0.000 claims description 10
- 102000018832 Cytochromes Human genes 0.000 claims description 9
- 108010052832 Cytochromes Proteins 0.000 claims description 9
- 230000036961 partial effect Effects 0.000 claims description 9
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims description 8
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 claims description 8
- 101000957383 Homo sapiens Cytochrome P450 2B6 Proteins 0.000 claims description 8
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 claims description 7
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 claims description 7
- 108700021672 human CYP3A Proteins 0.000 claims description 7
- 102000054928 human CYP3A Human genes 0.000 claims description 7
- -1 CYP2B1O Proteins 0.000 claims description 6
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims description 6
- 108010070675 Glutathione transferase Proteins 0.000 claims description 6
- 101000672024 Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 claims description 6
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims description 6
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims description 6
- 108091006172 SLC21 Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 229960004022 clotrimazole Drugs 0.000 claims description 6
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 6
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 claims description 5
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims description 5
- 102000005720 Glutathione transferase Human genes 0.000 claims description 5
- 101000690540 Homo sapiens Aryl hydrocarbon receptor Proteins 0.000 claims description 5
- 101000841498 Homo sapiens UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims description 5
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 5
- 101100385057 Mus musculus Cyp3a25 gene Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 102000047894 human CYP2B6 Human genes 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims description 4
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 4
- 101100464832 Homo sapiens PPARA gene Proteins 0.000 claims description 4
- 101100464833 Mus musculus Ppara gene Proteins 0.000 claims description 4
- 102000004357 Transferases Human genes 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- 238000012239 gene modification Methods 0.000 claims description 4
- 230000005017 genetic modification Effects 0.000 claims description 4
- 235000013617 genetically modified food Nutrition 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims description 3
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims description 3
- 101710104280 Cytochrome P450 1A2 Proteins 0.000 claims description 3
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 claims description 3
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims description 3
- 101000909131 Homo sapiens Cytochrome P450 2E1 Proteins 0.000 claims description 3
- 101000690535 Mus musculus Aryl hydrocarbon receptor Proteins 0.000 claims description 3
- 101100114686 Rattus norvegicus Cyp3a9 gene Proteins 0.000 claims description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 3
- 102000005421 acetyltransferase Human genes 0.000 claims description 3
- 108020002494 acetyltransferase Proteins 0.000 claims description 3
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 2
- 101100131294 Homo sapiens ABCC2 gene Proteins 0.000 claims description 2
- 101100001274 Homo sapiens AHR gene Proteins 0.000 claims description 2
- 101000855342 Homo sapiens Cytochrome P450 1A2 Proteins 0.000 claims description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 102000057459 human CYP1A2 Human genes 0.000 claims description 2
- 101100114663 Mus musculus Cyp2c55 gene Proteins 0.000 claims 2
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 claims 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 claims 1
- 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 claims 1
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 claims 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 claims 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims 1
- 101100316023 Mus musculus Uggt1 gene Proteins 0.000 claims 1
- 101100371717 Mus musculus Ugt1a1 gene Proteins 0.000 claims 1
- 101100371719 Mus musculus Ugt1a2 gene Proteins 0.000 claims 1
- 101100048299 Mus musculus Ugt1a6 gene Proteins 0.000 claims 1
- 102000000804 Pregnane X Receptor Human genes 0.000 claims 1
- 235000011449 Rosa Nutrition 0.000 claims 1
- 101150055214 cyp1a1 gene Proteins 0.000 claims 1
- 102000056262 human PPIG Human genes 0.000 claims 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 341
- 210000004027 cell Anatomy 0.000 description 203
- 241000699666 Mus <mouse, genus> Species 0.000 description 201
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 193
- 210000001519 tissue Anatomy 0.000 description 166
- 108010029704 Constitutive Androstane Receptor Proteins 0.000 description 114
- 102100038512 Nuclear receptor subfamily 1 group I member 3 Human genes 0.000 description 109
- 235000018102 proteins Nutrition 0.000 description 83
- 210000004185 liver Anatomy 0.000 description 76
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 45
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 37
- 229960002695 phenobarbital Drugs 0.000 description 36
- 108020004999 messenger RNA Proteins 0.000 description 35
- 230000004044 response Effects 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 32
- SIDLHXXVIBTSJZ-UHFFFAOYSA-N 7-phenylmethoxyquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1OCC1=CC=CC=C1 SIDLHXXVIBTSJZ-UHFFFAOYSA-N 0.000 description 30
- 101150053185 P450 gene Proteins 0.000 description 30
- 238000001262 western blot Methods 0.000 description 30
- 241000282412 Homo Species 0.000 description 27
- 230000037361 pathway Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 230000000717 retained effect Effects 0.000 description 24
- 241000894007 species Species 0.000 description 24
- 238000001727 in vivo Methods 0.000 description 23
- 238000003780 insertion Methods 0.000 description 23
- 230000037431 insertion Effects 0.000 description 23
- 229960003604 testosterone Drugs 0.000 description 23
- 239000002676 xenobiotic agent Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 238000005805 hydroxylation reaction Methods 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 239000000411 inducer Substances 0.000 description 19
- 210000001853 liver microsome Anatomy 0.000 description 19
- 230000002034 xenobiotic effect Effects 0.000 description 19
- 230000033228 biological regulation Effects 0.000 description 18
- 230000037396 body weight Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000004102 animal cell Anatomy 0.000 description 17
- 230000008901 benefit Effects 0.000 description 17
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 14
- 238000001952 enzyme assay Methods 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 12
- 240000008042 Zea mays Species 0.000 description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 12
- 235000005822 corn Nutrition 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 238000011813 knockout mouse model Methods 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 11
- 230000002440 hepatic effect Effects 0.000 description 11
- 238000011814 C57BL/6N mouse Methods 0.000 description 10
- 102000003839 Human Proteins Human genes 0.000 description 10
- 108090000144 Human Proteins Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000010200 validation analysis Methods 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 210000001671 embryonic stem cell Anatomy 0.000 description 9
- 210000005260 human cell Anatomy 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 231100000804 nongenotoxic Toxicity 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 101100440875 Mus musculus Cyp2b10 gene Proteins 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000037353 metabolic pathway Effects 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 230000002390 hyperplastic effect Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 206010068051 Chimerism Diseases 0.000 description 5
- 241000577979 Peromyscus spicilegus Species 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 108020001756 ligand binding domains Proteins 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 229960003793 midazolam Drugs 0.000 description 5
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000036578 sleeping time Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000012301 transgenic model Methods 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 4
- 101000919361 Homo sapiens Cytochrome P450 2C19 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- 102000018120 Recombinases Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 230000020335 dealkylation Effects 0.000 description 4
- 238000006900 dealkylation reaction Methods 0.000 description 4
- 102000057376 human CYP2C19 Human genes 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- XCRPPAPDRUBKRJ-UHFFFAOYSA-N quinolin-7-ol Chemical compound C1=CC=NC2=CC(O)=CC=C21 XCRPPAPDRUBKRJ-UHFFFAOYSA-N 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108020005065 3' Flanking Region Proteins 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 108020005029 5' Flanking Region Proteins 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 101150116544 CYP3A4 gene Proteins 0.000 description 3
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 3
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000037442 genomic alteration Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108700028732 mouse CYP3A Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229960000249 pregnenolone Drugs 0.000 description 3
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NWIAYUZWWLSLBI-UHFFFAOYSA-N 2-phenylmethoxyquinoline Chemical compound C=1C=C2C=CC=CC2=NC=1OCC1=CC=CC=C1 NWIAYUZWWLSLBI-UHFFFAOYSA-N 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 2
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150052538 CYP3A5 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 101150116929 Cyp2c55 gene Proteins 0.000 description 2
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 2
- 208000004752 Cytochrome P-450 Enzyme Inducers Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 2
- 108700041567 MDR Genes Proteins 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 101100400864 Mus musculus Abcb1a gene Proteins 0.000 description 2
- 101100400865 Mus musculus Abcb1b gene Proteins 0.000 description 2
- 101000640792 Mus musculus UDP-galactose translocator Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 101100400874 Rattus norvegicus Abcb1 gene Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000010420 art technique Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012733 comparative method Methods 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108090000280 major urinary proteins Proteins 0.000 description 2
- 102000003888 major urinary proteins Human genes 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 2
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100001092 no hepatotoxicity Toxicity 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZQWBOKJVVYNKTL-UHFFFAOYSA-N 1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine Chemical compound C1=CC(Cl)=CC=C1C1=C(C=NOCC=2C=C(Cl)C(Cl)=CC=2)N2C=CSC2=N1 ZQWBOKJVVYNKTL-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- WQVWZPZHJFKZIZ-UHFFFAOYSA-N 7-benzylquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1CC1=CC=CC=C1 WQVWZPZHJFKZIZ-UHFFFAOYSA-N 0.000 description 1
- 101150065145 ACADSB gene Proteins 0.000 description 1
- 101150077457 ACOX1 gene Proteins 0.000 description 1
- 101150054866 Acadl gene Proteins 0.000 description 1
- 101150113336 Acadm gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101150007356 Apoc1 gene Proteins 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101150081058 CPR gene Proteins 0.000 description 1
- 101150087009 CYB5A gene Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150107021 Cyp4a10 gene Proteins 0.000 description 1
- 101100152865 Danio rerio thraa gene Proteins 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101150086122 FDFT1 gene Proteins 0.000 description 1
- 101150071475 FDPS gene Proteins 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000640793 Homo sapiens UDP-galactose translocator Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 238000009013 Lowry's assay Methods 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101100440863 Mesocricetus auratus CYP2A9 gene Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 101100497133 Mus musculus Cyp2d26 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108091006525 SLC27A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108010075920 UDP-galactose translocator Proteins 0.000 description 1
- 102100033782 UDP-galactose translocator Human genes 0.000 description 1
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 1
- 101150115356 Ugt1a1 gene Proteins 0.000 description 1
- 102100023048 Very long-chain acyl-CoA synthetase Human genes 0.000 description 1
- 101000899479 Zea mays Trimethyltridecatetraene synthase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000364 carcinogenicity testing Toxicity 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006204 deethylation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 101150100705 ehhadh gene Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 101150014006 thrA gene Proteins 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012451 transgenic animal system Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/757,972 US7759541B2 (en) | 2004-12-13 | 2007-06-04 | Transgenic animals for assessing drug metabolism and toxicity |
| US11/757,972 | 2007-06-04 | ||
| PCT/GB2008/001897 WO2008149080A1 (en) | 2007-06-04 | 2008-06-04 | Transgenic animals for assessing drug metabolism and toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2008259618A1 true AU2008259618A1 (en) | 2008-12-11 |
Family
ID=39698732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008259618A Abandoned AU2008259618A1 (en) | 2007-06-04 | 2008-06-04 | Transgenic animals for assessing drug metabolism and toxicity |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7759541B2 (enExample) |
| EP (1) | EP2173160A1 (enExample) |
| JP (1) | JP2010528644A (enExample) |
| AU (1) | AU2008259618A1 (enExample) |
| CA (1) | CA2688438A1 (enExample) |
| IL (1) | IL202127A0 (enExample) |
| IN (1) | IN2009DN07390A (enExample) |
| WO (1) | WO2008149080A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| EP2218786B1 (en) * | 2007-11-14 | 2013-09-18 | National University Corporation Tottori University | Mammalian artificial chromosome vector comprising human cytochrome p450 gene (cluster), and non-human mammalian animal retaining the same |
| EP3417701B1 (en) | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| CN102286398B (zh) * | 2010-06-21 | 2014-06-04 | 中国科学院上海生命科学研究院 | 一种生产高活性和高纯度利福霉素sv的方法 |
| US20120023599A1 (en) * | 2010-07-23 | 2012-01-26 | Sigma-Aldrich Co. | Genome editing of cytochrome p450 in animals |
| RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| FR2979453B1 (fr) * | 2011-08-26 | 2016-01-08 | Olea Medical | Systeme et procede pour estimer une quantite d'interet d'un systeme dynamique artere/tissu/veine |
| RU2751240C2 (ru) * | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| NZ746089A (en) | 2012-09-07 | 2020-05-29 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
| ES2748662T3 (es) | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| US20140273031A1 (en) * | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | In-vitro method for monoclonal antibody production |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3430898A1 (en) * | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| EP3071024B1 (en) * | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| US9665718B2 (en) | 2014-03-14 | 2017-05-30 | International Business Machines Corporation | Correlating a task with commands to perform a change ticket in an IT system |
| KR102821645B1 (ko) | 2014-05-19 | 2025-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| SG10202103445QA (en) | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| JP2019524077A (ja) | 2016-06-27 | 2019-09-05 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｐ４５０オキシドレダクターゼ欠損を有するヒト肝臓キメラ非ヒト動物およびそれを使用する方法 |
| CN109182292B (zh) * | 2018-09-25 | 2022-02-08 | 安徽农业大学 | 一种草莓谷胱甘肽转移酶FaGST基因及其表达蛋白和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206906A4 (en) | 1999-08-13 | 2004-12-29 | Kirin Brewery | MOUSE CONTAINING A HUMAN P450 CYTOCHROME |
| EP1088900A1 (en) | 1999-09-10 | 2001-04-04 | Epidauros Biotechnologie AG | Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications |
| CA2426959C (en) | 2000-11-01 | 2011-10-04 | The University Of Sydney | Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation |
| AUPR446701A0 (en) | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
| JP2003304896A (ja) | 2002-04-15 | 2003-10-28 | Yasushi Yamazoe | ヒトｃｙｐ３ａ誘導能の測定法 |
| GB0216203D0 (en) | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
| AU2003278790A1 (en) * | 2002-09-09 | 2004-03-29 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| AU2005315438B2 (en) | 2004-12-13 | 2012-02-23 | Iti Scotland Limited | Transgenic animals for assessing drug metabolism and toxicity |
-
2007
- 2007-06-04 US US11/757,972 patent/US7759541B2/en not_active Expired - Fee Related
-
2008
- 2008-06-04 WO PCT/GB2008/001897 patent/WO2008149080A1/en not_active Ceased
- 2008-06-04 US US12/602,723 patent/US8624079B2/en not_active Expired - Fee Related
- 2008-06-04 IN IN7390DEN2009 patent/IN2009DN07390A/en unknown
- 2008-06-04 JP JP2010510871A patent/JP2010528644A/ja active Pending
- 2008-06-04 AU AU2008259618A patent/AU2008259618A1/en not_active Abandoned
- 2008-06-04 CA CA002688438A patent/CA2688438A1/en not_active Abandoned
- 2008-06-04 EP EP08762250A patent/EP2173160A1/en not_active Withdrawn
-
2009
- 2009-11-15 IL IL202127A patent/IL202127A0/en unknown
-
2010
- 2010-05-26 US US12/787,816 patent/US8212105B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20080148416A1 (en) | 2008-06-19 |
| US8212105B2 (en) | 2012-07-03 |
| EP2173160A1 (en) | 2010-04-14 |
| US20100257620A1 (en) | 2010-10-07 |
| IL202127A0 (en) | 2010-06-16 |
| JP2010528644A (ja) | 2010-08-26 |
| IN2009DN07390A (enExample) | 2015-07-24 |
| US20100235928A1 (en) | 2010-09-16 |
| CA2688438A1 (en) | 2008-12-11 |
| US8624079B2 (en) | 2014-01-07 |
| WO2008149080A1 (en) | 2008-12-11 |
| US7759541B2 (en) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8624079B2 (en) | Knockin mouse with a disruption in a PXR gene expressing human PXR | |
| Schmidt et al. | Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. | |
| US7781643B2 (en) | Transgenic non-human animals for pharmacological and toxicological studies | |
| Wu et al. | Conditional knockout of the mouse NADPH‐cytochrome p450 reductase gene | |
| Hasegawa et al. | Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line | |
| EP2209898B1 (en) | Two step cluster deletion and humanisation | |
| AU2005315438B2 (en) | Transgenic animals for assessing drug metabolism and toxicity | |
| US8809619B2 (en) | Knockout mice for a P450 gene cluster | |
| HK1102391B (en) | Transgenic animals for assessing drug metabolism and toxicity | |
| US20110119780A1 (en) | Screening for non-genotoxic carcinogens | |
| Wallace et al. | Inactivation of the murine Transferrin Receptor 2 gene using the Cre recombinase: loxP system | |
| AU2003284084A1 (en) | Screening systems and methods for identifying modulators of xenobiotic metabolism | |
| Class et al. | Patent application title: SCREENING FOR NON-GENOTOXIC CARCINOGENS Inventors: Charles Roland Wolf (Dundee, GB) Clifford Roy Elcombe (Dundee, GB) Assignees: ITI SCOTLAND LIMITED |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |